NCT02601911

Brief Summary

The aim of this study is effect of premedication on success of inferior alveolar nerve block injection. Sixty healthy adult volunteers including criteria, are participating. The patients will be divided into 3 groups and will be randomly given one of premedications including 1) 10 mg Ketorolac, 2) 10 mg Ketorolac plus 1000mg Acetaminophen, and 3)Placebo, 45 minutes before applying the injection. All patients will receive standard Inferior Alveolar Nerve Block injection . Patients with no lip numbness and positive responses to cold and electric pulp tests would be excluded from the study. Endodontic access preparation will be initiated 15 minutes after Inferior Alveolar Nerve Block injection. Pain during treatment will be recorded using a Heft parker Visual Analog Scale(VAS). Success will be considered as no or mild pain (VAS≤54) during caries/dentin removal, access cavity preparation and working lengths measurements. Data will be analysed using Mann-U-Whitney and Kruskal-wallis tests.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Sep 2015

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2015

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 27, 2015

Completed
15 days until next milestone

First Posted

Study publicly available on registry

November 11, 2015

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

September 20, 2016

Status Verified

September 1, 2016

Enrollment Period

8 months

First QC Date

October 27, 2015

Last Update Submit

September 17, 2016

Conditions

Keywords

FailureInjectionKetorolacPremedication

Outcome Measures

Primary Outcomes (1)

  • Pain rate using Visual Analog Scale (VAS) form

    Pain during caries and dentin removal , access cavity preparation and working lengths measurements using VAS form.

    45 minutes

Study Arms (3)

Ketorolac tromethanine

ACTIVE COMPARATOR

This group will receive a caplet including10 mg Ketorolac tromethamine 45 minutes before applying infra alveolar nerve block injection.

Drug: Ketorolac Tromethamine

Acetaminophen

ACTIVE COMPARATOR

This group receive a caplet including10 mg Ketorolac tromethamine/ 1000 mg Acetaminophen, before applying the injection.

Drug: Acetaminophen

Placebo

PLACEBO COMPARATOR

This group receive a caplet including placebo, before applying the injection.

Other: Placebo

Interventions

10 mg Ketorolac tromethamine is applied 45 minutes before the injection.

Also known as: Toradol
Ketorolac tromethanine

10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.

Also known as: non
Acetaminophen
PlaceboOTHER

This group receive the caplet including placebo 45 minutes before the injection.

Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with age ranged 18-65
  • without systemic diseases
  • without any medicine consumption
  • non smoking
  • non pregnant
  • non breast feeding
  • with asymptomatic irreversible pulpitis ( Visual Analog Scale ≤ 54) in one mandibular molar that needs root canal treatment
  • without any medicine consumption or analgesic and sedation
  • understand and sign the VAS and consent forms

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dental Branch, AZad UMS

Tehran, Tehran Province, Iran

Location

MeSH Terms

Interventions

Ketorolac TromethamineAcetaminophen

Intervention Hierarchy (Ancestors)

IndomethacinIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsAcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Study Officials

  • Nahid Mohammadzadeh Akhlaghi, DDS, MDS

    Associate Professor

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

October 27, 2015

First Posted

November 11, 2015

Study Start

September 1, 2015

Primary Completion

May 1, 2016

Study Completion

June 1, 2016

Last Updated

September 20, 2016

Record last verified: 2016-09

Locations